12:00 AM
Oct 15, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lurbinectedin: Preliminary Phase Ib data

Preliminary data from 23 patients in the dose-escalation portion of an open-label, U.S. Phase Ib trial in patients with major advanced solid tumors, excluding colorectal cancer, showed that PM01183 plus gemcitabine was well tolerated up to the MTD of 3.5 mg PM01183 plus 1,000 mg/m 2 gemcitabine. There was 1 death due to sepsis at the MTD. Dose-limiting...

Read the full 266 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >